Cheapest Tirzepatide Without Insurance

Almost every page ranking for this question is published by a company that sells the answer. That does not make them wrong, but it does mean the prices quoted are the ones that flatter the publisher. This page cites the manufacturer and the regulator, sells nothing, and makes no recommendation about which route you should take.

Self-pay prices, straight from the manufacturer

Lilly publishes its cash prices on its own coverage and savings page for Zepbound. The structure is dose-tiered, which is the detail that trips people up: the price you see quoted on a comparison site is usually the starting dose, and your cost rises as you escalate.

Why the $25 savings card probably does not apply to you

Search results for tirzepatide cost are full of a $25 figure. Read the condition attached to it: the Zepbound Savings Card requires commercial insurance. If you are uninsured, you do not qualify, and if you are on Medicare or Medicaid you are explicitly excluded as a government beneficiary. The $25 tier applies where commercial insurance covers the medication; there is a separate commercial-insurance-but-not-covered tier at $499 for the single-dose pen. None of these is a route for an uninsured buyer. Lilly's published terms for the card expire 31 December 2026.

So for someone genuinely without insurance, the honest field of options narrows quickly: manufacturer self-pay, retail pharmacy with a discount coupon, or compounded tirzepatide.

The compounding question, answered honestly

Compounded tirzepatide is frequently advertised below the manufacturer's self-pay prices. Two facts should shape how you read those offers.

First, regulatory status. The FDA's published position is unambiguous: compounded drugs are not FDA approved, and the agency does not review them for safety, effectiveness or quality before they are marketed. That is a statement about the category, not an accusation against any particular pharmacy.

Second, availability. Federal law generally restricts compounding copies of a commercially available drug, with shortage being the main circumstance that opens the door. FDA added tirzepatide injection to its drug shortage list in December 2022 and subsequently determined the shortage resolved, issuing a declaratory order to that effect in December 2024 after reconsidering an earlier October 2024 decision. The practical consequence is that the broad compounding of tirzepatide copies that characterised 2023 and 2024 no longer rests on the shortage justification it did then. Anyone offering it now should be able to explain on what basis, and a pharmacy's licensing status is a reasonable thing to ask about directly.

We are not telling you to avoid compounded tirzepatide, and we are not telling you to use it. We are telling you that "cheapest" and "equivalent" are different claims, and that the price gap exists partly because the products sit in different regulatory categories.

Working out your own cheapest route

A decision sequence rather than a single recommendation, because the answer depends on facts only you have.

1. Confirm you are genuinely uninsured for this. Many plans exclude weight-management drugs specifically while covering everything else. If you have commercial insurance and the exclusion is the obstacle rather than the absence of a plan, the appeal route is a real option and often a cheaper one than cash. Our guide to getting Zepbound covered sets out the deadlines and the documentation.
2. Check whether a second indication applies. Zepbound is approved both for weight management and, since December 2024, to treat moderate to severe obstructive sleep apnoea in adults with obesity. A plan that excludes weight-loss drugs may still cover a sleep apnoea indication. This is a question for your prescriber and worth asking before you commit to paying cash indefinitely.
3. Price your actual maintenance dose, not the starting dose. The figure that matters is what you will pay at 10 or 15 mg, not the $299 headline. For most people that is $449 with timely refills.
4. Diarise the 45-day refill window. At 10 mg and above, missing it costs $250. Set the reminder the day the prescription is delivered.
5. Compare against retail with a discount coupon. Coupon savings off a list price above $1,000 generally do not get you near $449, but the arithmetic is worth doing for your own pharmacy rather than assumed.
6. If you consider compounded, verify the pharmacy. State board licensure, a named prescriber, and a clear answer about the basis on which it is being compounded.

Where tracking actually saves money here

Most of this page is pricing, which an app cannot change. One part of it an app genuinely can. The $250-a-month exposure at 10 mg and above is triggered by a date, not by a clinical event, and the window runs from the delivery of the previous prescription rather than from the day you happen to think of it.

If you are logging doses anyway, the refill date is derivable from the log, and a reminder set against the delivery date is the difference between $449 and $699. Jabby tracks dose dates and supports reminders, which is a mundane use of a tracker and, at these prices, among the most valuable.

Frequently asked questions

What is the cheapest way to get tirzepatide without insurance?

For the FDA-approved product, Lilly's self-pay pricing is the cheapest published route: $299 a month at 2.5 mg, $399 at 5 mg, and $449 at 7.5 mg and above when refilled within 45 days. Compounded tirzepatide is often advertised for less, but it is not an FDA-approved product and is not reviewed by the agency for safety, effectiveness or quality before marketing.

How much is tirzepatide per month without insurance at a regular pharmacy?

Retail list prices for brand tirzepatide sit well above the self-pay figures above, and published third-party reports of retail and coupon prices vary widely enough that we will not quote a single number here. Price your own pharmacy directly. The manufacturer self-pay route exists precisely because the retail cash price is high.

Does the $25 Zepbound savings card work without insurance?

No. Lilly's published terms require commercial insurance for the savings card, and government beneficiaries including Medicare and Medicaid enrollees are excluded. The uninsured route is the self-pay pricing, not the card.

Why did my Zepbound price jump to $699?

Most likely the refill window. At 10 mg, 12.5 mg and 15 mg the self-pay price is $449 with the purchase offer and $699 at the regular price, and the offer requires completing the refill within 45 days of the previous delivery. The same jump at 7.5 mg is $449 to $499.

Is compounded tirzepatide safe?

We cannot answer that for any specific pharmacy and will not pretend otherwise. What is on the record is the FDA's own position that compounded drugs are not FDA approved and are not reviewed by the agency for safety, effectiveness or quality before they are marketed. Discuss it with your prescriber and verify the pharmacy's licensing.

Is Mounjaro cheaper than Zepbound for weight loss?

They are the same active ingredient under different approvals: Mounjaro is approved for type 2 diabetes and Zepbound for weight management and obstructive sleep apnoea. Pricing programmes differ by product and change, and prescribing one for the other's indication is a clinical and coverage question rather than a shopping decision. Our tirzepatide maintenance dose guide covers how the two products differ in what their labels actually say.

Related guides

• How to get Zepbound covered by insurance: prior authorisation, the appeal deadlines and the external review right
• Tirzepatide maintenance dose after weight loss: what each product's label says once you reach your goal
• How long Zepbound lasts in the fridge: storage limits, which matter more when you are paying cash
• Zepbound diet plan: the eating structure that protects what you are paying for
• GLP-1 tracker app: dose logging and the refill reminder that keeps you inside the 45-day window

Sources

• Eli Lilly and Company. Zepbound Coverage, Affordability and Savings. Read 8 October 2026. Source for: self-pay KwikPen prices of $299 at 2.5 mg, $399 at 5 mg and $449 at 7.5 mg and above; regular prices of $499 at 7.5 mg and $699 at 10, 12.5 and 15 mg; the 45-day refill condition; the $25 savings card requiring commercial insurance; the exclusion of government beneficiaries including Medicare and Medicaid; savings card terms expiring 31 December 2026.
• US Food and Drug Administration. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. Read 8 October 2026. Source for: "compounded drugs are not FDA approved" and that the agency "does not review compounded drugs for safety, effectiveness or quality before they are marketed".
• US Food and Drug Administration. Compounding and the FDA: Questions and Answers. Source for: the general framework governing when compounding a copy of a commercially available drug is permitted.
• US Food and Drug Administration. Declaratory order on the tirzepatide injection products shortage, December 2024. Source for: tirzepatide added to the shortage list in December 2022, the October 2024 decision, and the December 2024 order concluding the shortage is resolved.
• Eli Lilly and Company. ZEPBOUND (tirzepatide) injection prescribing information. Source for: the two approved indications, weight management and moderate to severe obstructive sleep apnoea in adults with obesity.